Bradmer Medical Isotope Supply For Phase III Trial Secure



    TSX: BMR

    TORONTO, Dec. 10 /CNW/ - Bradmer Pharmaceuticals Inc., a
biopharmaceutical company dedicated to the development and commercialization
of cancer therapies, today announced that the start of Company's planned Phase
III trial of Neuradiab, a murine monoclonal antibody radiolabeled with
Iodine-131 (I-131), is unaffected by the recent shortage of medical isotopes
from a nuclear facility in Chalk River, Ontario. Bradmer procures its I-131
material used to prepare Neuradiab from commercial sources outside North
America as well as a back up facility that are not affected by the recent
events at Chalk River.
    "The medical isotope production issues have received a significant amount
of attention recently, and we felt it would be appropriate to update our
shareholders and stakeholders on the situation as it relates to Bradmer. We
made decisions earlier this year that ensured both the clinical and commercial
supplies of the radioisotope for our product candidate, Neuradiab," said Alan
M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "Our
formulation work, completed earlier this year, indicated that the I-131 we use
yielded consistent and reproducible product which we have validated for
clinical use at a commercial scale for the upcoming Phase III trial. In
addition, we have made contingency plans to ensure we can modify our protocol
accordingly to conduct the imaging flow studies that are required in our Phase
III trial if the shortage of Technetium as a diagnostic agent continues due to
the current events."
    Bradmer has invested the better part of the past year securing and
validating the commercial production of Neuradiab. The Company has completed
the final validation phase of the manufacturing process for the drug and will
present a complete chemistry, manufacturing and controls (CMC) update to the
United States Food and Drug Administration (FDA) for their review and meet
with them for further guidance later this quarter. Following the completion of
this meeting, the subsequent update of the regulatory documents, and pending
the necessary regulatory approvals, Bradmer will be in a position to initiate
the Phase III trial early in 2008.
    Bradmer's proposed Phase III trial, evaluating Neuradiab as a treatment
for primary glioblastoma multiforme (GBM), is a randomized two arm
multi-center study targeting 380 patients in each arm comparing the current
standard of care with a group receiving Neuradiab as an adjunct to the current
standard of care.

    About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

    Bradmer Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of new and innovative cancer therapies.
Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University
Medical Center as a proprietary therapy for a particularly aggressive form of
brain cancer, glioblastoma multiforme. To date, over US$60 million in grants
and related support has driven research and development of the licensed
treatment, which has been delivered to over 200 patients with promising
results and has completed Phase II clinical trials at Duke University. Bradmer
is currently in the process of organizing a pivotal multi-center clinical
trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status
by both the U.S. Food and Drug Administration and the European Medicines
Agency.

    Bradmer Pharmaceuticals Inc.'s common shares have not been registered
under the Securities Act of 1933, as amended (the "Securities Act") or any
state regulatory agency in the United States. The resale or transfer by a U.S.
investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to
the requirements of Rule 904 of Regulation S of the Securities Act or such
other applicable exemption thereunder, and other applicable state securities
laws.

    Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risks and
uncertainties, which may include but are not limited to, the receipt of all
regulatory approvals required to conduct the proposed clinical trial of
Neuradiab, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from time
to time in the Company's ongoing quarterly and annual reporting.





For further information:

For further information: Bradmer Pharmaceuticals Inc., Mr. Brian
Brohman, Chief Business Officer, Phone: (416) 361-6058 (Ext. 804), E-mail:
bbrohman@bradmerpharma.com, Internet: www.bradmerpharma.com; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail: rmarshall@equicomgroup.com

Organization Profile

BRADMER PHARMACEUTICALS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890